Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | STS | P08842 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SCN1A | P35498 | 1/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.48 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL110657 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2HTTNPC1RAB9ASTS | |
| SCHEMBL28239717 | 0.84 | SCN1A (0.46) | SMN1; SMN2HTTNPC1RAB9ASTS | |
| SCHEMBL27647562 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2HTTNPC1RAB9ASTS | |
| SCHEMBL27667920 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2HTTNPC1RAB9ASTS | |
| SCHEMBL27668237 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2HTTNPC1RAB9ASTS | |
| SCHEMBL27647433 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2HTTNPC1RAB9ASTS | |
| SCHEMBL27647429 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2HTTNPC1RAB9ASTS | |
| SCHEMBL27647410 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2HTTNPC1RAB9ASTS | |
| SCHEMBL27647587 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2HTTNPC1RAB9ASTS | |
| SCHEMBL18821723 | 0.83 | MAPT (0.62) | SMN1; SMN2HTTNPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2913052-A1 | Phototherapy compositions and methods | OMJ Ireland Limited (PR) | 2015-09-02 | — | — | EP | claimed |
| EP-1674095-B1 | Phototherapy compositions | OMJ IRELAND LTD (PR) | 2014-08-20 | — | — | EP | claimed |
| EP-1674095-A1 | Phototherapy compositions | OMJ Ireland Limited (PR) | 2006-06-28 | — | — | EP | claimed |
| US-20060134031-A1 | Phototherapy compositions and methods | MALLINCKRODT ENTERPRISES LLC | 2006-06-22 | — | — | US | claimed |
| EP-2913052-A1 | Phototherapy compositions and methods | OMJ Ireland Limited (PR) | 2015-09-02 | — | — | EP | disclosed |
| EP-1674095-B1 | Phototherapy compositions | OMJ IRELAND LTD (PR) | 2014-08-20 | — | — | EP | disclosed |
| US-8481008-B2 | Phototherapy compositions and methods | THERAKOS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120039825-A1 | PHOTOTHERAPY COMPOSITIONS AND METHODS | MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) | 2012-02-16 | — | — | US | disclosed |
| US-8057785-B2 | Phototherapy compositions and methods | OMJ IRELAND LIMITED (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2009097490-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20090189127-A1 | Optical resin lens and production method for optical resin material | KONICA MINOLTA OTPO, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-1717607-A1 | OPTICAL RESIN LENS AND METHOD FOR PRODUCING OPTICAL RESIN MATERIAL | Konica Minolta Opto, Inc. (JP) | 2006-11-02 | — | — | EP | disclosed |
| EP-1674095-A1 | Phototherapy compositions | OMJ Ireland Limited (PR) | 2006-06-28 | — | — | EP | disclosed |
| US-20060134031-A1 | Phototherapy compositions and methods | MALLINCKRODT ENTERPRISES LLC | 2006-06-22 | — | — | US | disclosed |
| CN-1246300-C | Resorcinol derivatives | PFIZER (US) | 2006-03-22 | — | — | CN | disclosed |
| CN-1344250-A | Resorcinol derivatives | PFIZER (US) | 2002-04-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134031-A1 | Phototherapy compositions and methods | VCL, TYR, TTPA | SMN1; SMN2 3516/4885HTT 3211/4885NPC1 2551/4885 |
| US-20120039825-A1 | PHOTOTHERAPY COMPOSITIONS AND METHODS | VCL, TYR, TTPA | SMN1; SMN2 3516/4885HTT 3211/4885NPC1 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.